Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Metagenomi Therapeutics, Inc.MGX · Entity 7270 | Director | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Metagenomi Therapeutics, Inc.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Ending reported balance
After 2026-09-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-09 · Purchase · Acquired 19,883 · Balance 19,883 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Row 2 · 2026-09-09 · Purchase · Acquired 117 · Balance 20,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Decibel Therapeutics, Inc.
Report date September 25, 2023 · Filed September 25, 2023
Section 16 reporting ended · disclosed 2023-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 1
1 source rowRow 1 · 2023-09-25 · Disposition to issuer · Disposed 220,849 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer held by the reporting person were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3: Includes 195,000 unvested Company RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2032-02-24 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-25 · Disposition to issuer · Disposed 187,500 · Balance 0 F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2033-03-15 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-25 · Disposition to issuer · Disposed 72,000 · Balance 0 F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2030-12-07 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-25 · Disposition to issuer · Disposed 1,072,539 · Balance 0 F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer held by the reporting person were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"),
F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU.
F3: Includes 195,000 unvested Company RSUs.
F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time.
F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR.
KalVista Pharmaceuticals, Inc.
Report date June 11, 2026 · Filed June 11, 2026
Section 16 reporting ended · disclosed 2026-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.07 · Expires 2034-11-24 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option vests over a 36 month period: 1/36th on December 25, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger").
F2: The option vests over a 36 month period: 1/36th on December 25, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date.
F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 23:51 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | PurchaseCommon Stock | 117 | $1.18 | $138.06 |
DisclosureSEC source: 0001193125-26-389550 · ownership.xml · nonDerivative · entry 2 Reid Laurence · CIK 0001492749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 23:51 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | PurchaseCommon Stock | 19,883 | $1.17 | $23,263.11 |
DisclosureSEC source: 0001193125-26-389550 · ownership.xml · nonDerivative · entry 1 Reid Laurence · CIK 0001492749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,883 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:30 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $10.07 | Not disclosed |
DisclosureSEC source: 0001492749-26-000002 · form4-06112026_080604.xml · derivative · entry 1 Reid Laurence · CIK 0001492749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2034-11-24 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option vests over a 36 month period: 1/36th on December 25, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 18:31 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 17,400 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001193125-26-267272 · ownership.xml · derivative · entry 1 Reid Laurence · CIK 0001492749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,400 Underlying: Common Stock · 17,400 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| September 02, 2025 Filed Sep 2, 2025 20:44 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0000950170-25-112535 · ownership.xml · derivative · entry 1 Reid Laurence · CIK 0001492749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2035-09-01 F1 · derivative.exercise_date: 33% of the shares subject to this option shall vest and become exercisable on September 2, 2026, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| November 23, 2024 Filed Nov 26, 2024 21:41 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $10.07 | $0.00 |
DisclosureSEC source: 0001415889-24-027736 · form4-11262024_091149.xml · derivative · entry 1 Reid Laurence · CIK 0001492749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-11-22 F1 · derivative.exercise_date: The option vests over a 36 month period: 1/36th on December 25, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 20:25 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 1,072,539 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0000899243-23-019490 · doc4.xml · derivative · entry 4 Reid Laurence · CIK 0001492749 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,072,539 shares Expires 2030-12-07 F5 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. F5 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 20:25 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 72,000 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0000899243-23-019490 · doc4.xml · derivative · entry 3 Reid Laurence · CIK 0001492749 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,000 shares Expires 2033-03-15 F4 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 20:25 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 187,500 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0000899243-23-019490 · doc4.xml · derivative · entry 2 Reid Laurence · CIK 0001492749 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 187,500 shares Expires 2032-02-24 F4 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 20:25 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerCommon Stock | 220,849 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019490 · doc4.xml · nonDerivative · entry 1 Reid Laurence · CIK 0001492749 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer held by the reporting person were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2 · shares: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3 · shares: Includes 195,000 unvested Company RSUs. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer held by the reporting person were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2 · price: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:24 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Options (right to buy) · Derivative | 72,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0000899243-23-008873 · doc4.xml · derivative · entry 2 Reid Laurence · CIK 0001492749 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2033-03-15 F3 · derivative.exercise_date: The option was granted on March 16, 2023. The shares underlying the option are scheduled to vest with respect to 40% of the shares on January 26, 2024, and with respect to the remainder on January 26, 2025. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:24 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantCommon Stock | 195,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008873 · doc4.xml · nonDerivative · entry 1 Reid Laurence · CIK 0001492749 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,849 F1 · shares: Consists of shares of the Issuer's common stock issuable under 195,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest with respect to 40% of the shares on January 26, 2024, and with respect to the remainder on January 26, 2025. F2 · balance_after: Includes 195,000 unvested RSUs. Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 21:36 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000899243-22-008086 · doc4.xml · derivative · entry 1 Reid Laurence · CIK 0001492749 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2032-02-24 F1 · derivative.exercise_date: The option was granted on February 25, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 25, 2023 and with respect to the remainder in 36 equal monthly installments thereafter through February 25, 2026. Read SEC document |
| September 15, 2021 Filed Sep 18, 2021 01:48 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | PurchaseCommon Stock | 10,000 | $7.64 | $76,400.00 |
DisclosureSEC source: 0000899243-21-036500 · doc4.xml · nonDerivative · entry 1 Reid Laurence · CIK 0001492749 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,849 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.587 to $7.65, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.